CD44 and neoplasm: Further modifications led to the creation of D4RA6H, designed from the DMBT1 sequence (GRVEVLXXXXW), with the “XXXX” motif replaced by an arginine-rich sequence (RRRR) for siRNA binding, and fused with a CD44-targeting moiety (KPSSPPEEHH) to increase tumour cell selectivity.